Clinical Trials
29 trialsPembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
Thomas Jefferson University
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Yale University
MK-0683-014
Merck Sharp & Dohme LLC
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
AIDS Malignancy Consortium
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
University of Wisconsin, Madison
NSCLC
Fox Chase Cancer Center
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
Milton S. Hershey Medical Center
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
Dartmouth-Hitchcock Medical Center
VICTORY-J
Kanazawa University
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
Stanford University
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
University of Washington
Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer
University of Virginia
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
Merck Sharp & Dohme LLC
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Milton S. Hershey Medical Center
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Merck Sharp & Dohme LLC
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
Merck Sharp & Dohme LLC
A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
Merck Sharp & Dohme LLC
A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
Merck Sharp & Dohme LLC
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
University of Colorado, Denver
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
Istituto Clinico Humanitas
MESO-02
University College, London
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Merck Sharp & Dohme LLC